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From Form to Function: Minireview
Signaling by Protein
Tyrosine Phosphatases
Nicholas K. Tonks* and Benjamin G. Neel† role in neuronal targeting, since the D69D/99A mutant
is more defective than the DPTP69D mutant. Loss-of-*Cold Spring Harbor Laboratory
function mutations in DLAR illustrate a role in controllingCold Spring Harbor, New York 11724–2208
the ability of different, but overlapping, subsets of neu-†Cancer Biology Program
rons to navigate through various migration choice pointsDivision of Hematology-Oncology
and to innervate the appropriate muscle targets (Krue-Department of Medicine
ger et al., 1996). Similar phenotypes are observed inBeth Israel Hospital
gain-of-function mutants in adhesion molecules suchBoston, Massachusetts 02215
as fasciclin II, suggesting that the adhesion molecules
and RPTPs may affect the same signaling pathways or
modulate signal transduction events that converge onTyrosine phosphorylation, controlled by thecoordinated
common downstream targets. These observations sup-actions of protein tyrosine phosphatases (PTPs) and
port a critical role for RPTPs in regulating the adhesivekinases (PTKs), is a critical control mechanism for nu-
events that control axonal pathfinding. Tyrosine phos-merous physiological processes, including growth, dif-
phorylation-dependent pathways involving homologs offerentiation, metabolism, cell cycle regulation and cy-
FGFR or Eph family PTKs are potential targets for thesetoskeletal function. Originally, PTKs were believed to be
PTPs.the key enzymes controlling the dynamic process of
The identification of candidate ligands for PTPz/b sug-tyrosine phosphorylation in vivo, with a small number
gests a role for mammalian RPTPs in control of neuronalof PTPs playing largelyhousekeeping roles. Unexpected
adhesion. PTPz/b is expressed on glia and its extracellu-structural diversity within a large family of PTPs called
lar segment is characterized by an N-terminal carbonicthis idea into question. Approximately 75 PTPs have
anhydrase (CA)-like domain. This domain lacks key cata-been identified, including both receptor-like and non-
lytic residues in CA, and instead, functions as a bindingtransmembrane enzymes, with genome sequencing
pocket for a specific heterophilic ligand, contactin, adata predicting the existence of z500 human PTPs.
glyco-phosphatidylinositol-anchored neuronal cell rec-These enzymes are characterized by the presence of a
ognition molecule (Peles et al., 1995). The CA domainconserved catalytic domain of z240 residues, con-
of PTPz/b can act as a substrate for neuronal adhesion
taining the unique signature motif, [I/V]HCxAGxxR[S/
and the induction of neurite outgrowth and differentia-
T]G that defines this enzyme family (see accompanying
tion; in such assays, surface contactin expression is
minireview by Denu et al., 1996 [this issue of Cell]), fused,
required for neurons to respond. During neuronal devel-
at either the N- or C-terminal ends, toa variety of noncat-
opment, contactin-PTPz/b interactions may mediate
alytic, regulatory sequences. Now, several studies have
uni- or bidirectional signaling pathways between glia
illustrated subtleties of regulation and diversity of func-
and neurons. Although contactin binds to PTPz/b, and
tion for the PTPs which at least match those of thePTKs.
PTPz/b affects contactin function, no effect of contactin
Furthermore, PTPs can have both positive and negative
on either PTPz/b enzymatic activity or downstream path-
effects on cellular signaling. This minireview discusses
ways regulated by this RPTP has been demonstrated.
selected recent examples in which insights have been
The effect of the PTPz/b ectodomain on contactin ar-
gained into the physiological function of PTP family gues for caution in interpreting the phenotypes of the
members. Drosophila RPTP mutants; some or even all of the ob-
served defects could result from loss of the ability of
Receptor-PTPs and Cell Adhesion RPTPs to function as ligands, independent of their ca-
Receptor-PTPs (RPTPs) consist of an intracellular seg- pacity to dephosphorylate.
ment containing one or two phosphatase domains, a RPTPs in Regulation of Adherens Junctions
single transmembrane domain and a variable extracellu- The ectodomains of PTPm and PTPk display similarity
lar segment. The ectodomains of many RPTPs contain to Ig superfamily members. These RPTPs participate in
structural features suggesting a role in cell-cell or cell- homophilic binding interactions. PTPm and PTPk do not
matrix adhesion, a suggestion now confirmed by a com- interact with each other, indicating specificity in these
bination of genetic analyses and the identification of interactions. PTPm (Brady-Kalnay et al., 1995) and PTPk
homotypic or heterotypic ligands and binding proteins. (Fuchs et al., 1996), along with other less well-defined
RPTPs and Regulation of Neuronal Adhesion PTPs, have now beenshown toassociate with cadherin–
Four of the five RPTP genes identified in Drosophila catenin complexes in various tissues and cell lines.
encode adhesion molecule-like PTPs expressed selec- Cadherins are implicated in tissue development and
tively in the nervous system. Recently, mutant embryos morphogenesis and represent the adhesive component
lacking expression of some of these RPTPs were gener- in adherens junctions. Association between the intracel-
ated. Disruption of DPTP69D results in pupal lethality. lular portion of cadherins and the actin cytoskeleton,
In the mutant embryos motor neuron growth cones show mediated by catenins, is essential for adhesion. Disrup-
defects in their ability to recognize muscle targets, or tion of this multiprotein complex abrogates adhesion
follow pathways that bypass these targets altogether and may result in invasion and/or metastasis. Several
(Desai et al., 1996). Although mutants lacking DPTP99A cytoplasmic and RPTKs have been shown to phosphor-
ylate components of the cadherin–catenin complex withshow no detectable phenotype, this RPTP also has a
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concomitant disruption of adhesion. Therefore, rather “substrate-trapping” mutants of the SHPs should help
to identify the proximal SHP-1 target(s) in these path-than acting as adhesion molecules themselves, PTPs
such as PTPm and PTPk likely regulate the tyrosine ways. It also is unclear why SHP-1 appears to be re-
cruited to cytokine receptors (e.g., the EPOR) substan-phosphorylation and thus, the adhesive properties of
cadherins. This may contribute to the mechanism by tially before dephosphorylation of Jaks is detected; a
second event may be required to activate SHP-1.which cell–cell contact is stabilized and growth is inhib-
ited in, for example, confluent cell cultures. SHP-1 also regulates oligomeric receptor signaling.
Activation through the B cell antigen receptor (BCR)
is abrogated upon co-crosslinking of the inhibitory Fc
Regulation of Growth Factor, Cytokine, and receptor (FcR), FcgRIIB; this serves to attenuate anti-
Oligomeric Receptor Signaling by SHPs body production in the presence of circulating immune
Nontransmembrane PTPs containing SH2 domains complexes. Mutation of a specific FcgRIIB tyrosyl resi-
(SHPs) have been identified in species as diverse as due eliminates its ability to block B cell activation. A
mammals, Xenopus and Drosophila. Two SHPs exist in phosphotyrosyl peptide comprising this sequence binds
higher organisms. SHP-1 is expressed at highest levels SHP-1, a 70 kDa protein subsequently identified as
in hematopoietic cells. The motheaten (me/me) mouse, SHP-2 and a 150 kDa protein, which may be the inositol
caused by absence of SHP-1, provides a murine model monophosphatase SHIP (Ono et al., 1996). Since me/me
of SHP-1 deficiency. SHP-2, and its likely Drosophila mice were found to be refractory to FcgRIIB-mediated
homolog Corkscrew (CSW), are expressed ubiquitously. inhibition, a model was proposed in which SHP-1 is a
Whether an additional SHP exists in Drosophila or critical signaling molecule used by FcgRIIB to terminate
whether, instead, CSW also subserves SHP-1 functions BCR signals. Interestingly, FcgRIIB engagement does
remains to be determined. not result in major changes in tyrosyl phosphorylation,
The presence of SH2 domains in PTPs suggested suggesting that FcgRIIB-bound SHP-1 has a limited
that these molecules might interact with known PTK number of targets (D’Ambrosio et al., 1995). However,
signaling pathways. Recent evidence, combining bio- SHP-1 is not generally required for FcgRIIB-mediated
chemical and genetic approaches, validates this notion. inhibition. FcgRIIB also blocks activation signals gener-
Pathways regulated by the two SHPs have been speci- ated through FceR, but FcgRIIB-mediated inhibition is
fied, and several potential targets identified. Remark- normal in mast cells from me/me mice (Ono et al., 1996).
ably, despite their shared domain structure and consid- Instead, SHIP likely plays a key role in FcgRIIB signaling
erable (55%) overall sequence identity, the SHPs appear in mast cells (Ono et al., 1996). It is not clear whether
to have distinct biological roles. Early studies indicated and/or why FcgRIIB uses distinct signaling pathways in
that SHP-1 was predominantly a negative regulator of mast cells and B cells. Both SHIP and an SHP could be
PTK signaling, whereas SHP-2 and CSW played a posi- necessary for inhibition. Perhaps SHP-2 can substitute
tive (i.e., signal enhancing) role. More recent work, al- for SHP-1 in mast cells but not B cells (Ono et al., 1996).
though not conclusive, raises the possibility that de- Alternatively, the actions of SHP-1 and SHIP could con-
pending on the specific signaling pathway, SHPs may verge to produce similar effects, with different cell types
have positive or negative effects. using predominantly one or the other.
SHP-1 Regulates Multiple Signaling Pathways A motif similar to that in FcgRIIB, now termed the ITIM
in Hematopoietic Cells (immune receptor tyrosine-based inhibitory motif), also
The motheaten mouse displays a panoply of hematopoi- is found in other receptors, notably killer-inhibitory re-
etic abnormalities, affecting virtually every lineage. It ceptors (KIRs) of NK cells and the B cell co-receptor
now is clear that SHP-1 negatively regulates hematopoi- CD22. KIRs bind MHC class 1 antigens and prevent
etic signaling pathways downstream of cytokine recep- activating receptors on NK cells from directing lysis of
tors, oligomeric receptors, such as antigen and Fc re- host cells. SHP-1 is recruited to KIRs and phosphotyro-
ceptors, and receptor tyrosine kinases (RTKs), syl peptides from the KIR ITIM activate SHP-1 in vitro.
Upon EPO stimulation, cells expressing EPO receptor Furthermore, over-expression of a presumptive domi-
mutants unable to recruit SHP-1 display prolonged ty- nant negative (C->S) mutant of SHP-1 blocks KIR-medi-
rosyl phosphorylation of the receptor-associated PTK ated inhibition (Burshtyn et al., 1996). However, since
Jak2 and an enhanced mitogenic response (Klingmuller SHP-1, SHP-2 and SHIP all can bind to a similar motif
et al., 1995). Likewise, interferon a–stimulated macro- (although with differing affinities), it is difficult to be cer-
phages from me/me mice exhibit markedly increased tain from these experiments that SHP-1 alone mediates
tyrosyl phosphorylation of Jak 1, suggesting that one KIR signals. SHP-1 also binds tightly to CD22, and it
general function of SHP-1 may be to inactivate Janus has been proposed that this interaction helps set the
family PTKs (Jaks). However, not all Jaks (even those threshold for BCR activation (Doody et al., 1995). This
activated by the same cytokine receptor) are inactivated model is consistent with elegant genetic studies of mice
by SHP-1, as interferon a–induced Tyk2 activation is expressing transgenic BCRs in the me/me background
comparable in normal and me/me macrophages (David (Cyster and Goodnow, 1995). However, it has not been
et al., 1995). It is not clear whether SHP-2 or another demonstrated directly that CD22 ITIMs are required for
PTP (perhaps an RPTP) substitutes for SHP-1 in these CD22-mediated inhibition.
pathways. These studies are consistent with the hypoth- SHP-1 also binds to tyrosyl phosphorylated c-Kit and
esis that SHP-1 regulates at least some cytokine recep- becomes tyrosyl phosphorylated in response to Kit li-
tor-associated Jaks, but direct dephosphorylation of gand stimulation. Two groups crossed mice bearing ki-
nase-defective mutants of c-Kit (Wv/1 mice) with me/1Jaks by SHP-1 has not been demonstrated. Use of novel
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mice, and the F1 progeny were intercrossed to generate provocative, no direct evidence for tyrosine phosphory-
lation of CTLA-4 has been presented; thus, the natureall possible allelic combinations of SHP-1 and c-Kit. The
results indicate that SHP-1 negatively regulates c-Kit in of the proposed interaction between CTLA-4 and SHP-2
is unclear. Furthermore, it is not clear that the putativehematopoietic progenitors and that excess c-Kit signal-
ing is an important contributor to the motheaten pheno- SHP-2 binding site is required for CTLA-4 function; nota-
bly, this site differs from other known high affinity bind-type (Lorenz et al., 1996; Paulson et al., 1996). Again,
however, SHP-1 does not negatively regulate c-Kit in all ing sites for SHP-2, all of which have isoleucine, valine,
or leucine at the 13 position. Thus, it is possible thatcell types. These studies provide compelling genetic
evidence for the importance of SHP-1 regulation of c-Kit SHP-2’s interaction with CTLA-4 requires an intermedi-
ate protein. Most importantly, it is not clear whether thein vivo. Moreover, the tissue-specificity of this regulation
emphasizes the complexity of the interplay between observed hyperactivation of T cell signaling components
is the cause of the lymphoproliferation in CTLA-4 miceeven a single RTK and PTP in the context of the whole
organism. as opposed to an indirect consequence of the increased
number of activated T cells in these mice.Identification of a Presumptive CSW Substrate
CSW is a required positive component of the Torso
pathway, which directs Drosophila embryonic head and PTPs and Dephosphorylation of MAP
tail development. Recent work by two groups (Herbst Kinases (MAPKs)
et al., 1996; Raabe et al., 1996), using biochemical and MAP kinase (MAPK) family members are essential com-
genetic approaches, establishes that CSW also regu- ponents in several signaling pathways. For activation,
lates Sevenless signaling, most likely by dephosphory- MAPKs require phosphorylation by a dual specificity
lating the Daughter of sevenless (DOS) protein. These kinase of both the Tyr and Thr residues in the sequence
studies suggest that dephosphorylation of DOS by CSW TXY found in their activation loops. A significant body
is required to generate a positive signal needed for Sev- of literature implicates dual specificity phosphatases,
enless signaling. However, although DOS may be a di- such as MKP-1, in the dephosphorylation of MAP ki-
rect substrate of CSW, the data do not exclude the nases in vivo. However, recent work indicates that PTPs
possibility that CSW actually targets a PTK that controls also play key roles in regulating at least some MAPKs.
DOS phosphorylation. Likewise, the precise pathway(s) A MAPK-dependent pathway linking changes in environ-
in which CSW and DOS participate remain unclear. The mental stimuli to the onset of mitosis has been charac-
structure of DOS, which contains an N-terminal PH do- terized in S. pombe. In this pathway the MAPK Spc1/
main and multiple potential tyrosine phosphorylation Sty1, the homolog of S. cerevisiae Hog1, is inactivated
sites, is reminiscent of the mammalian proteins Gab1, by specific dephosphorylation of Y173 by the PTPs Pyp1
IRS-1 and IRS-2. Intriguingly, these proteins all bind and Pyp2 (Shiozaki and Russell, 1996; Wilkinson et al.,
SHP-2, and appear to serve as scaffolding proteins 1996). Spc1/Sty1 also is implicated in regulation of a
downstream of mammalian receptor PTKs (RTKs), but distinct pathway in sexual development in response to
the precise pathways that they regulate are not fully environmental stress (Shiozaki and Russell, 1996; Wil-
understood. Given their structure, one possibility is that kinson et al., 1996). Spc1/Sty1 activation evokes the
they collect secondary signaling molecules, which are stress-induced phosphorylation of the transcription fac-
then released by dephosphorylation so they may partici- tor Atf-1, which in turn is required for inductionof meiotic
pate indownstream signaling. It is not clear which down- genes. One such gene encodes Pyp2, which dephosph-
stream pathway(s) is(are) regulated by CSW and SHP-2. orylates Y173 of Spc1/Sty1 in a feedback inhibition loop.
In the Sevenless pathway, CSW must be either upstream It is likely that analogous PTPs are involved in regulation
and downstream of Raf or operate in a parallel pathway. of some MAPK pathways in higher eukaryotes.
Multiple studies in Xenopus and mammals have placed
SHP-2 upstream of MAPK. Perhaps CSW and SHP-2 do
Perspectiveshave multiple points of action in RTK signaling. Alterna-
To understand fully the function of PTPs, it is necessarytively, SHP-2/CSW might not act directly on RTK signal-
to identify physiological substrates of the individual fam-ing pathways, per se, but instead could function in a
ily members. An approach to this problem has now beenpathway that is permissive for RTK signaling, for exam-
developed, involving the use of “substrate-trapping”ple in response to attachment to ECM.
PTP mutants. Substrate trapping mutants retain similarSHP-2 as a Negative Regulator of T cell Signaling
affinity for substrate to that of the wild type enzyme butSHP-2 associates with and may be responsible for inhib-
their catalytic activity is markedly reduced, to such anitory signals delivered through CTLA-4, a negative regu-
extent that an enzyme-substrate complex, once formed,lator of T cell activation (Marengere et al., 1996). CTLA-4
is stable enough to withstand isolation and thus allowknockout mice display lymphoproliferation, with marked
identification of the substrate. Mutant PTPs in which theincreases in activated lymphocytes. SHP-2 co-immuno-
catalytically-essential, nucleophilic Cys residue from theprecipitates with CTLA-4 and a phosphotyrosyl peptide
signature motif has been mutated to Ser or Ala are inac-derived from the CTLA-4 sequence (pY201VKM) binds
tive but in some cases retain the ability to bind to sub-SHP-2 in vitro, reportedly via SHP-2’s SH2 domains. T
strate in vitro. However, not all such mutant PTPs bindcells from lymph nodes of CTLA-4 knockout mice reveal
stably to substrates in the cell. A novel substrate-trap-marked increases in Fyn, Lck, and ZAP-70 activity, sug-
ping mutant has been developed in which the invariantgesting that recruitment of SHP-2 to CTLA-4 inactivates
aspartate, which functions as a general acid to pro-TCR signaling as binding of SHP-1 to CD22 is proposed
to inactivate BCR signals. Although these findings are tonate the tyrosyl leaving group of substrates (Denu et
Cell
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Marengere,L.E. M., Waterhouse, P., Duncan, G.S.,Mittrucker, H.-W.,al., 1996 [this issueof Cell]), is changed to alanine. Asp->
Feng, G.-S., and Mak, T.W. (1996). Science 272, 1170–1173.Ala trapping mutants appear to be much more efficient
Ono, M., Bolland, S., Tempst, P., and Ravetch, J.V. (1996). Naturesubstrate traps than Cys->Ser/Ala mutants of the same
383, 263–266.PTP (Garton et al., 1996). It is important to recognize
Paulson, R.F., Vesely, S., Siminovitch, K.A., and Bernstein, A. (1996).that, in light of their potential to serve as substrate traps,
Nature Genet. 13, 309–315.
Cys->Ser/Ala and Asp->Ala mutant PTPs may not be
Peles, E., Nativ, M., Campbell, P.L., Sajurai, T., Martinez, R., Lev,appropriate choices for dominant-negative mutants.
S., Clary, D.O., Schilling, J., Barnea, G., Plowman, G.D., Grumet, M.,
One can envisage that formation of a stable complex and Schlessinger, J. (1995). Cell 82, 251–260.
between a “substrate-trap” and a pTyr residue that is Raabe, T., Riesgo-Escovar, J., Liu, X., Bausenwein, B.S., Deak, P.,
critical to a signaling event may antagonize interactions Maroy, P., and Hafen, E. (1996). Cell 85, 911–920.
between the substrate and its downstream targets and Shiozaki, K., and Russell, P. (1996). Genes Dev. 10, 2276–2288.
actually be functionally equivalent to dephosphorylation Wilkinson, M.G., Samuels, M., Takeda, T., Toone, W.M., Shieh, J.-C.,
by a wild type PTP. A mutant with reduced activity and Toda, T., Millar, J.B. A., and Jones, N. (1996). Genes Dev. 10, 2289–
2301.substrate affinity, as would be produced by altering the
invariant Arg in the signature motif or a deletion mutant,
would be more appropriate.
Use of the Asp->Ala mutant has already illustrated a
somewhat unexpected restricted substrate specificity
of PTP-PEST for p130cas, contradicting the generally ac-
cepted view that all PTPs are promiscuous (Garton et
al., 1996). Since this aspartate residue is invariant in PTP
family members, such a strategy should be generally
applicable to any PTP and may represent a powerful
tool with which to delineate physiological substrates
and function. Such novel biochemical approaches, com-
bined with genetic analysis, should lead to rapid under-
standing of the biological function of PTPs.
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